Company Overview

Alaunos Therapeutics, Inc. (Alaunos Therapeutics) is a clinical-stage biotechnology company focused on developing engineered cell therapies for the treatment of solid tumors. The company operates within the biotechnology and oncology therapeutics industries, with a specific emphasis on T cell receptor–engineered T cell (TCR‑T) therapies designed to target intracellular cancer antigens. Its core scientific platform centers on leveraging the Sleeping Beauty transposon system, a non-viral gene delivery technology licensed from academic institutions, to engineer autologous T cells.

The company’s primary product candidates were designed to target KRAS mutations, which are among the most prevalent oncogenic drivers in solid tumors such as pancreatic, colorectal, and lung cancers. Alaunos’ strategy aimed to address historically difficult-to-treat cancers by enabling T cells to recognize mutation-specific tumor antigens. The company traces its origins to ZIOPHARM Oncology, Inc., which was founded in 2003 and later rebranded as Alaunos Therapeutics in 2022 to reflect its focus on TCR‑T cell therapy development. Its evolution included a transition from small-molecule oncology drugs to advanced cell-based immunotherapies.

Business Operations

Alaunos Therapeutics historically operated as a single-segment biotechnology company focused on cell therapy research and development, with no approved commercial products and no recurring product revenue. Revenue generation was primarily limited to collaboration-related income and financing activities, while the majority of expenditures were directed toward research and development, clinical trials, and regulatory compliance.

The company’s operations included preclinical research, early-stage clinical trials, and manufacturing process development for autologous TCR‑T therapies. Alaunos relied on a combination of internal scientific teams and external contract research organizations for clinical execution. Its technology portfolio was built around licensed intellectual property, including TCR constructs and the Sleeping Beauty gene transfer platform. Public disclosures indicate no material revenue-generating subsidiaries, and information regarding active joint ventures or large-scale commercial partnerships is limited based on available public sources.

Strategic Position & Investments

Strategically, Alaunos positioned itself as a developer of next-generation solid tumor immunotherapies by targeting shared oncogenic mutations rather than lineage-specific surface antigens. Its growth strategy centered on advancing multiple KRAS-targeted TCR programs into clinical evaluation and expanding its TCR library to address additional intracellular tumor targets.

The company’s most notable strategic assets included its licensed technologies and its research collaboration history with major academic cancer centers, including intellectual property originating from The University of Texas MD Anderson Cancer Center. Alaunos pursued capital raises through public equity markets to fund operations. Public filings and disclosures indicate that the company later explored strategic alternatives, including restructuring options, as financial constraints and clinical development challenges emerged. Certain aspects of the company’s current investment posture and asset status are data inconclusive based on available public sources, particularly following restructuring-related announcements.

Geographic Footprint

Alaunos Therapeutics was headquartered in the United States, with corporate operations historically based in Texas. Its operational footprint was primarily domestic, focused on U.S.-based research, clinical trial oversight, and administrative functions. Clinical development activities were conducted at selected investigational sites, largely within North America.

International presence was limited and primarily indirect, consisting of global intellectual property rights and potential future applicability of its therapies to international oncology markets. There is no verified public evidence of significant overseas manufacturing facilities or commercial operations, and the company’s global influence remained largely tied to scientific collaboration rather than direct foreign operations.

Leadership & Governance

Alaunos Therapeutics was led by executives with experience in biotechnology, cell therapy development, and corporate restructuring. The company was governed by a board of directors responsible for strategic oversight, capital allocation, and evaluation of strategic alternatives during periods of financial and operational transition. Leadership communications emphasized scientific innovation, capital discipline, and reassessment of development priorities.

Key executives disclosed in public filings included:

• Michel Azoulay – Chief Executive Officer
• Catherine J. Moukheiber – Chief Financial Officer
• Michael Zauderer – Chief Operating Officer
• John M. Baldino – Chief Accounting Officer

Elements of the current leadership structure and governance framework are data inconclusive based on available public sources, particularly following restructuring-related disclosures and changes in operational status.